127 related articles for article (PubMed ID: 38522403)
1. Circadian rhythms in CYP2A5 expression underlie the time-dependent effect of tegafur on breast cancer.
Yoshida Y; Fukuda T; Tanihara T; Nishikawa N; Iwasa S; Adachi S; Zaitsu O; Terada Y; Tsukamoto R; Shimoshikiryo H; Fukuoka K; Tsurusaki F; Hamamura K; Oyama K; Tsuruta A; Koyanagi S; Matsunaga N; Ohdo S
Biochem Biophys Res Commun; 2024 May; 708():149813. PubMed ID: 38522403
[TBL] [Abstract][Full Text] [Related]
2. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
[TBL] [Abstract][Full Text] [Related]
3. Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes.
Komatsu T; Yamazaki H; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2000 Dec; 28(12):1457-63. PubMed ID: 11095583
[TBL] [Abstract][Full Text] [Related]
4. Association analysis of CYP2A6 genotypes and haplotypes with 5-fluorouracil formation from tegafur in human liver microsomes.
Wang H; Bian T; Liu D; Jin T; Chen Y; Lin A; Chen C
Pharmacogenomics; 2011 Apr; 12(4):481-92. PubMed ID: 21521021
[TBL] [Abstract][Full Text] [Related]
5. Formation pathways of gamma-butyrolactone from the furan ring of tegafur during its conversion to 5-fluorouracil.
Yamamiya I; Yoshisue K; Matsushima E; Nagayama S
Drug Metab Dispos; 2010 Aug; 38(8):1267-76. PubMed ID: 20463005
[TBL] [Abstract][Full Text] [Related]
6. Cytosolic and microsomal activation of doxifluridine and tegafur to produce 5-fluorouracil in human liver.
Ozawa S; Hamada M; Murayama N; Nakajima Y; Kaniwa N; Matsumoto Y; Fukuoka M; Sawada J; Ohno Y
Cancer Chemother Pharmacol; 2002 Dec; 50(6):454-8. PubMed ID: 12451471
[TBL] [Abstract][Full Text] [Related]
7. Expression of CYP2A6 in tumor cells augments cellular sensitivity to tegafur.
Murayama N; Sai K; Nakajima Y; Kaniwa N; Ozawa S; Ohno Y; Sawada J
Jpn J Cancer Res; 2001 May; 92(5):524-8. PubMed ID: 11376561
[TBL] [Abstract][Full Text] [Related]
8. Circadian expression of the steroid 15 alpha-hydroxylase (Cyp2a4) and coumarin 7-hydroxylase (Cyp2a5) genes in mouse liver is regulated by the PAR leucine zipper transcription factor DBP.
Lavery DJ; Lopez-Molina L; Margueron R; Fleury-Olela F; Conquet F; Schibler U; Bonfils C
Mol Cell Biol; 1999 Oct; 19(10):6488-99. PubMed ID: 10490589
[TBL] [Abstract][Full Text] [Related]
9. The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer.
Kaida Y; Inui N; Suda T; Nakamura H; Watanabe H; Chida K
Clin Pharmacol Ther; 2008 Apr; 83(4):589-94. PubMed ID: 18212800
[TBL] [Abstract][Full Text] [Related]
10. CYP2A6 and the plasma level of 5-chloro-2, 4-dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1.
Fujita K; Yamamoto W; Endo S; Endo H; Nagashima F; Ichikawa W; Tanaka R; Miya T; Araki K; Kodama K; Sunakawa Y; Narabayashi M; Miwa K; Ando Y; Akiyama Y; Kawara K; Kamataki T; Sasaki Y
Cancer Sci; 2008 May; 99(5):1049-54. PubMed ID: 18380793
[TBL] [Abstract][Full Text] [Related]
11. A novel mutant allele of the CYP2A6 gene (CYP2A6*11 ) found in a cancer patient who showed poor metabolic phenotype towards tegafur.
Daigo S; Takahashi Y; Fujieda M; Ariyoshi N; Yamazaki H; Koizumi W; Tanabe S; Saigenji K; Nagayama S; Ikeda K; Nishioka Y; Kamataki T
Pharmacogenetics; 2002 Jun; 12(4):299-306. PubMed ID: 12042667
[TBL] [Abstract][Full Text] [Related]
12. Circadian Regulation of Hepatic Cytochrome P450 2a5 by Peroxisome Proliferator-Activated Receptor
Deng J; Guo L; Wu B
Drug Metab Dispos; 2018 Nov; 46(11):1538-1545. PubMed ID: 30154104
[TBL] [Abstract][Full Text] [Related]
13. Characteristic CYP2A6 genetic polymorphisms detected by TA cloning-based sequencing in Chinese digestive system cancer patients with S-1 based chemotherapy.
Fang WJ; Mou HB; Jin DZ; Zheng YL; Zhao P; Mao CY; Peng L; Huang MZ; Xu N
Oncol Rep; 2012 May; 27(5):1606-10. PubMed ID: 22322240
[TBL] [Abstract][Full Text] [Related]
14. Modulatory effects of 5-fluorouracil on the rhythmic expression of circadian clock genes: a possible mechanism of chemotherapy-induced circadian rhythm disturbances.
Terazono H; Hamdan A; Matsunaga N; Hayasaka N; Kaji H; Egawa T; Makino K; Shigeyoshi Y; Koyanagi S; Ohdo S
Biochem Pharmacol; 2008 Apr; 75(8):1616-22. PubMed ID: 18329632
[TBL] [Abstract][Full Text] [Related]
15. [Tegafur and 5-FU concentrations in cancerous and normal tissues in nude mice after oral administration of UFT].
Murahashi I; Honda M; Mukae K; Hosoya Y; Takasaki E
Gan To Kagaku Ryoho; 1987 Dec; 14(12):3265-9. PubMed ID: 3120643
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2A6 genetic polymorphism on the metabolic conversion of tegafur to 5-fluorouracil and its enantioselectivity.
Yamamiya I; Yoshisue K; Ishii Y; Yamada H; Chiba M
Drug Metab Dispos; 2014 Sep; 42(9):1485-92. PubMed ID: 25002745
[TBL] [Abstract][Full Text] [Related]
17. Rat cytochrome p450 1A and 3A enzymes involved in bioactivation of tegafur to 5-fluorouracil and autoinduced by tegafur in liver microsomes.
Yamazaki H; Komatsu T; Takemoto K; Shimada N; Nakajima M; Yokoi T
Drug Metab Dispos; 2001 Jun; 29(6):794-7. PubMed ID: 11353746
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of S-1 and CYP2A6 genotype in Japanese patients with advanced cancer.
Hirose T; Fujita K; Nishimura K; Ishida H; Yamashita K; Sunakawa Y; Mizuno K; Miwa K; Nagashima F; Tanigawara Y; Adachi M; Sasaki Y
Oncol Rep; 2010 Aug; 24(2):529-36. PubMed ID: 20596643
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes.
Asikainen A; Tarhanen J; Poso A; Pasanen M; Alhava E; Juvonen RO
Toxicol In Vitro; 2003 Aug; 17(4):449-55. PubMed ID: 12849728
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of chemotherapy of breast cancer (2). Clinical evaluation of the blood and tissue concentrations of FT-207 following intrarectal administration].
Hiraide H; Mimura K; Kawano M; Hatsuse K; Kadota T; Kurokawa T; Tamaki K; Kanabe S; Mizoguchi O; Terashima H; Iwasa H
Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 1):992-6. PubMed ID: 6408994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
